A new combination treatment built around the targeted drug daraxonrasib shrank or eliminated tumours in more than six in ten patients with advanced pancreatic cancer, according to results presented at a major cancer conference in Barcelona this week. In one in twelve patients, tumours disappeared entirely on scans.
FAKTA
- 61 patients with metastatic pancreatic cancer received daraxonrasib plus chemotherapy as their first treatment.
- Tumours shrank or disappeared in 60.7% of patients; 8.2% had complete responses, with no tumour visible on scans.
- The treatment held the disease in check in 90.2% of patients; median progression-free survival was 12.8 months.
- 76.6% of patients were still alive after 12 months.
- The results were presented on 20 November 2026 at the EORTC-NCI-AACR symposium in Barcelona.
Deep Responses in a Hard-to-Treat Cancer
The findings come from the phase I/II RMC-GI-102 trial, in which patients whose pancreatic cancer had already spread received 200 milligrams of daraxonrasib as a daily pill, together with two standard chemotherapy drugs, gemcitabine and nab-paclitaxel, given by intravenous drip. The data covered patients treated up to 28 September 2026, with a median follow-up of 18.3 months.
Presenting the results, Dr Wungki Park, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York, said the combination produced deeper responses than doctors had seen before, with disease control lasting nearly twice as long as is typical with chemotherapy alone. Disease control lasted a median of 12.8 months, and more than three quarters of patients were alive at one year.
Targeting the Cancer’s Engine
Daraxonrasib works differently from older cancer drugs. It targets the RAS protein, a growth signal that drives most pancreatic tumours. More than 90% of pancreatic cancers carry a mutation in the KRAS gene, which keeps that signal switched on. The drug blocks the active form of RAS, cutting off the instructions that help cancer cells survive and multiply.
The drug, sold under the brand name RASONQUE, was approved by the United States Food and Drug Administration in August 2026 for patients whose cancer had already been treated. That approval followed a large phase III trial, RASolute 302, in which daraxonrasib nearly doubled median survival, to 13.2 months against 6.6 months with chemotherapy, in previously treated patients.
Cautious Optimism
Doctors stressed that the new results come from an early-phase study with no comparison group, so they cannot yet prove how much better the combination is than chemotherapy alone. Only 5% of patients stopped treatment because of side effects linked to daraxonrasib, and the drug was generally tolerated better than chemotherapy in the earlier large trial.
A larger randomised phase III trial, RASolute 303, is now under way to compare daraxonrasib, alone and combined with chemotherapy, directly against standard chemotherapy in newly diagnosed patients. Pancreatic cancer is often diagnosed only after it has spread, and survival rates remain among the lowest of any major cancer, so researchers say any treatment that deepens responses at the start of therapy could matter. More international coverage is available on Watan News.































